12:00 AM
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ME-143: Phase I data

An open-label, U.S. Phase I trial in 15 patients with refractory solid tumors showed that once-weekly 2.5, 5, 10 and 20 mg/kg doses of IV ME-143 were generally well tolerated with 1 serious infusion reaction at the highest dose reported. Additionally, 5 mg/kg IV...

Read the full 200 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >